Title:
COMBINATION THERAPY FOR TREATING DISEASE
Document Type and Number:
WIPO Patent Application WO2003034977
Kind Code:
A3
Abstract:
Disclosed are methods for treating cancer comprising administering a xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen in present in the host serum, which antigen does not elicit a host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen.
Inventors:
SCHULTES BIRGIT C (US)
NICODEMUS CHRISTOPHER F (US)
NOUJAIM ANTOINE (CA)
NICODEMUS CHRISTOPHER F (US)
NOUJAIM ANTOINE (CA)
Application Number:
PCT/IB2002/005794
Publication Date:
May 27, 2004
Filing Date:
October 28, 2002
Export Citation:
Assignee:
ALTAREX MEDICAL CORP (CA)
SCHULTES BIRGIT C (US)
NICODEMUS CHRISTOPHER F (US)
NOUJAIM ANTOINE (CA)
SCHULTES BIRGIT C (US)
NICODEMUS CHRISTOPHER F (US)
NOUJAIM ANTOINE (CA)
International Classes:
A61K39/395; C07K16/30; (IPC1-7): A61K39/395
Domestic Patent References:
| WO2001012217A1 | 2001-02-22 |
Other References:
NG B. ET AL.: "Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts", CANCER RESEARCH, vol. 61, 1 April 2001 (2001-04-01), pages 2996 - 3001, XP002963364
GOLD D.V. ET AL.: "Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin", INT. J. CANCER, vol. 57, 1994, pages 204 - 210, XP002963400
GOLD D.V. ET AL.: "Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin", INT. J. CANCER, vol. 57, 1994, pages 204 - 210, XP002963400
Download PDF:
Previous Patent: FEED TUBE SYSTEM FOR ENTERAL FEEDING
Next Patent: ANTIDIABETIC 2-SUBSTITUTED-5'-O- (1-BORANOTRIPHOSPHATE) ADENOSINE DERIVATIVES
Next Patent: ANTIDIABETIC 2-SUBSTITUTED-5'-O- (1-BORANOTRIPHOSPHATE) ADENOSINE DERIVATIVES